Upcoming event
Masterclass on Functional urology
Back

Tag: ASCO21

ASCO 2021: The field of bladder cancer is experiencing a fantastic boom, and here is a selection of all the exciting news

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study

ASCO 2021 features Keynote-564 study results, an update on Keynote-426, and an analysis of the CLEAR trial

KEYNOTE-564 study

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC)

The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES

PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center

Diagnostic performance of Gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging in early-relapsed prostate cancer: Phase 3, prospective, multicenter study (IAEA-PSMA study)

Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes